Coming next month in JACS, and online now: Distal cholangiocarcinoma and pancreas cancer


Distal cholangiocarcinoma and pancreas cancer: A 13-institution study from the U.S. extrahepatic biliary malignancy consortium and the central pancreas consortium

Cecilia G. Ethun, MD; Alexandra G. Lopez-Aguiar, MD; Timothy Pawlik, MD, MPH, PhD, FACS; and colleagues found that while distal cholangiocarcinoma (DC) and pancreatic ductal adenocarcinoma (PDAC) are distinct entities, DC has a more favorable prognosis than PDAC. Current adjuvant therapy regimens are only associated with improved survival in PDAC, not DC. Treatment paradigms used for PDAC should not be extrapolated to DC, despite similar operative approaches, and novel therapies for DC should be explored.

This article and all other JACS content is available online.

Tagged as: ,


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611


Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store